AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Symbicort (budesonide/formoterol) by Year
Symbicort (budesonide/formoterol) — Europe product sales ($M) ($M)
AstraZeneca Symbicort (budesonide/formoterol): $560M in FY2025, up 0.2% from a year earlier.
Where the FY2025 figure comes from
“|| Symbicort | 2,885 | - | - | 1,193 | 1 | 801 | (1) | 1 | 560 | - | (3) | 331 | 1 | 3”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Symbicort (budesonide/formoterol) — Europe product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 560 | +0.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 559 | +1.8% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 549 | -5.7% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 582 | -13.1% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 670 | -3.5% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 694 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up symbicort (budesonide/formoterol)
Cite this data
StockData. (2026). AstraZeneca Symbicort (budesonide/formoterol) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-symbicort-eu
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.
See a number that looks wrong?